A Phase 3 interventional study of Ranibizumab and Laser in Branch Retinal Vein Occlusion, sponsored by Novartis Pharmaceuticals. Completed at 82 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-10.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies testing ranibizumab in Retinal Vein Occlusion — none open to participants now, none under way, none of them phase 3. Ranibizumab · Retinal Vein Occlusion.
Among the 47 studies testing ranibizumab in Retinal Vein Occlusion, this one is the 2nd largest by enrollment, is one of 5 that started in 2012, is one of 13 in phase 3, and was the 26th registered.
289 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.
Browse Retinal Vein Occlusion studies →None of the 47 studies testing ranibizumab in Retinal Vein Occlusion is open now. The open studies under Retinal Vein Occlusion, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 12 · Phase 3 14 · Phase 4 13
First in 2006; this study’s year is marked. 5 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 455 is above the median of 51 across 208 interventional studies indexed under Retinal Vein Occlusion.
Median enrollment 56 across the 47 interventional studies. Of the 36 that completed or were terminated, 18 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 47 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
20 studies in Retinal Vein Occlusion by Novartis: none open now, none under way, none of them phase 3. Of 20 finished, 14 (70%) have results posted.
Among the 20 studies in Retinal Vein Occlusion by Novartis, this one is the 2nd largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2012, is one of 11 in phase 3, and was the 8th registered.
Novartis’s Retinal Vein Occlusion studies by the year they started, since 2008.
None of the studies under way reaches primary completion within a year.
Among the 47 studies testing ranibizumab in Retinal Vein Occlusion, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 20 in Retinal Vein Occlusion:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will generate comparative data for 0.5-mg ranibizumab using PRN dosing administered with or without adjunctive laser treatment versus laser photocoagulation (the current standard of care) up to Month 6 in patients with visual impairment due to ME secondary to BRVO. Additionally the results of this study will provide long-term (24-month) safety and efficacy data for ranibizumab, administered with or without adjunctive laser treatment in this indication.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ranibizumab 0.5 mg
Drug: Ranibizumab
Ranibizumab 0.5 mg + laser
Drug: Ranibizumab · Procedure: Laser
Laser monotherapy with Ranibizumab 0.5 mg from Month 6
Procedure: Laser
Also known as: Lucentis
laser photocoagulation
Mean Change in Visual Acuity: BCVA Change at Month 6 Compared to Baseline in Patients With Visual Impairment Due to Branch Retinal Vein Occlusion (BRVO)
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 6 compare to Baseline, the 95% confidence interval and P value (related to the null hypothesis that this mean change is equal to zero) based on a t distribution/t test were calculated and assessed by an ANOVA model.
Time frame: Baseline, 6 Months
The Mean Average Change in Visual Acuity From Month 1 Through Month 24 Compared to Baseline
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. (A positive average change from baseline of BCVA indicates improvement): Mean Average Change: for each patient, first average change is calculated as the average of the changes from baseline to Month 1 over Month 24. Then, mean average change is calculated as the average of average changes across all patients.
Time frame: Baseline, 24 Months
Number of Ranibizumab Treatments From Day 1 to Month 23 by Treatment Group
Number of injections provided to the patients during the 23 month period and conducted within FAS with LOCF and observed data.
Time frame: Day 1 through Month 23
Mean Average Change in Visual Acuity (BCVA Letters) From Month 1 Through Month 6
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters.(A positive average change from baseline of BCVA indicates improvement): Mean Average Change: for each patient, first average change is calculated as the average of the changes from baseline to Month 1 over Month 6. Then, mean average change is calculated as the average of average changes across all patients.
Time frame: From Baseline through Month 6
The Mean Change in Visual Acuity BCVA (Letters) From Baseline at Month 12 and Month 24
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 12 and Month 24 compare to Baseline, the 95% confidence interval and P value (related to the null hypothesis that this mean change is equal to zero) based on a t distribution/t test were calculated and were assessed by an ANOVA model.
Time frame: Baseline, Month 12 and Month 24
The Percent of Patients With a Visual Acuity Gain of ≥1, ≥5, ≥10, ≥15, and ≥30 Letters From Baseline up to Month 6 and Month 24, by Visit
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An increased score indicates improvement in acuity. This outcome assessed the number of participants who had improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 letters of visual acuity at Month 6 \& Month 24 as compared with baseline, was assessed by an ANOVA model. Endpoints related to the proportion of patients with BCVA letter gain or loss from Baseline was analyzed via stratified Cochran-Mantel-Haenszel test with stratification based on baseline BCVA (baseline BCVA less than or equal to 39, 40 to 59, greater than or equal to 60 letters, treatment groups).
Time frame: Baseline, Month 6 and Month 24
Number of Patients With a BCVA Improvement vs Baseline or Achieving Greater Than or Equal to 73 Letters at Month 6 in the Study Eye
Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and Month 6 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at Month 6 indicates a positive outcome.
Time frame: Month 6
Number of Patients With a BCVA Improvement vs Baseline or Achieved Greater Than or Equal to 73 Letters at Month 24 in the Study Eye
Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and Month 12 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at Month 24 indicates a positive outcome.
Time frame: Month 24
The Mean Change in Central Reading Center-assessed Central Subfield Thickness From Month 12 and Month 24 vs. Baseline by Treatment Arm
Retinal thickness was measured using Optical Coherence Tomography (OCT). The images were reviewed by a central reading center to ensure a standardized evaluation. Stratification was done based on categories of baseline best corrected visual acuity \& analysis was based on analysis of variance (ANOVA)
Time frame: Month 12 and Month 24
The Mean Change in Patient Reported Outcomes in NEI-VFQ-25 Score (Composite Score and Subscales) at Month 6 and Month 24 Compared to Baseline
The survey consists of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. All items are scored so that a high score represents better functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. In this format scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score.
Time frame: Months 6 and 24
BCVA (Letters) Mean Average Change From First Ranibizumab Treatment to Month 24 in the Study Eye for Patients Randomized to the Laser Monotherapy Arm
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 24 compare to Baseline, the 95% confidence interval and P value (related to the null hypothesis that this mean change is equal to zero) based on a t distribution/t test were calculated and assessed by an ANOVA model.
Time frame: Month 24
| Milestone | 1-ranibizumab Monotherapy | 2-ranibizumab With Laser | 3-laser Monotherapy |
|---|---|---|---|
| Started | 183 | 180 | 92 |
| Completed 6 mos | 174 | 170 | 80 |
| Completed | 161 | 154 | 65 |
| Not completed | 22 | 26 | 27 |
| Withdrew: Administrative issue | 1 | 0 | 1 |
| Withdrew: Physician decision | 2 | 0 | 7 |
| Withdrew: Protocol violation | 0 | 3 | 0 |
| Withdrew: Death | 2 | 1 | 2 |
| Withdrew: Lost to follow-up | 3 | 3 | 3 |
| Withdrew: Withdrawal by subject | 11 | 11 | 10 |
| Withdrew: Adverse event | 3 | 8 | 4 |
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 6 compare to Baseline, the 95% confidence interval and P value (related to the null hypothesis that this mean change is equal to zero) based on a t distribution/t test were calculated and assessed by an ANOVA model.
| letters | 1-ranibizumab Monotherapy | 2-ranibizumab With Laser | 3-laser Monotherapy |
|---|---|---|---|
| Baseline | 59.5 ± 11.78 | 56.6 ± 13.19 | 56.8 ± 13.86 |
| Month 6 | 74.3 ± 12.27 | 71.4 ± 14.43 | 62.8 ± 14.08 |
| Change from Baseline atMonth 6 | 14.8 ± 10.70 | 14.8 ± 11.13 | 6.0 ± 14.27 |
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. (A positive average change from baseline of BCVA indicates improvement): Mean Average Change: for each patient, first average change is calculated as the average of the changes from baseline to Month 1 over Month 24. Then, mean average change is calculated as the average of average changes across all patients.
| letters | 1-ranibizumab Monotherapy | 2-ranibizumab With Laser | 3-laser Monotherapy |
|---|---|---|---|
| Baseline | 59.5 ± 11.78 | 56.6 ± 13.19 | 56.8 ± 13.86 |
| Average Month 1 toMonth 24 | 74.5 ± 12.11 | 72.0 ± 13.56 | 65.9 ± 13.24 |
| Change from Baseline | 15.0 ± 10.86 | 15.4 ± 10.76 | 9.1 ± 13.49 |
Number of injections provided to the patients during the 23 month period and conducted within FAS with LOCF and observed data.
| treatments | 1-ranibizumab Monotherapy | 2-ranibizumab With Laser |
|---|---|---|
| Number of Ranibizumab Treatments From Day 1 to Month 23 by Treatment Group | 11.4 ± 5.76 | 11.3 ± 6.03 |
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters.(A positive average change from baseline of BCVA indicates improvement): Mean Average Change: for each patient, first average change is calculated as the average of the changes from baseline to Month 1 over Month 6. Then, mean average change is calculated as the average of average changes across all patients.
| letters | 1-ranibizumab Monotherapy | 2-ranibizumab With Laser | 3-laser Monotherapy |
|---|---|---|---|
| Baseline | 59.5 ± 11.78 | 56.6 ± 13.19 | 56.8 ± 13.86 |
| Average Month 1 to Month 6 | 72.7 ± 11.49 | 69.7 ± 13.38 | 61.7 ± 12.66 |
| Change from Baseline | 13.2 ± 9.60 | 13.2 ± 9.89 | 4.8 ± 11.69 |
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 12 and Month 24 compare to Baseline, the 95% confidence interval and P value (related to the null hypothesis that this mean change is equal to zero) based on a t distribution/t test were calculated and were assessed by an ANOVA model.
| letters | 1-ranibizumab Monotherapy | 2-ranibizumab With Laser | 3-laser Monotherapy |
|---|---|---|---|
| Baseline | 59.5 ± 11.78 | 56.6 ± 13.19 | 56.8 ± 13.86 |
| Month 12 | 74.9 ± 12.87 | 72.3 ± 15.31 | 66.8 ± 13.87 |
| Change from baseline Month 12 | 15.4 ± 12.25 | 15.7 ± 13.12 | 10.0 ± 14.33 |
| Month 24 | 75.0 ± 14.65 | 73.9 ± 14.59 | 68.4 ± 15.26 |
| Change from baseline Month 24 | 15.5 ± 13.91 | 17.3 ± 12.61 | 11.6 ± 16.09 |
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An increased score indicates improvement in acuity. This outcome assessed the number of participants who had improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 letters of visual acuity at Month 6 \& Month 24 as compared with baseline, was assessed by an ANOVA model. Endpoints related to the proportion of patients with BCVA letter gain or loss from Baseline was analyzed via stratified Cochran-Mantel-Haenszel test with stratification based on baseline BCVA (baseline BCVA less than or equal to 39, 40 to 59, greater than or equal to 60 letters, treatment groups).
| percent patients gaining improvement | 1-ranibizumab Monotherapy | 2-ranibizumab With Laser | 3-laser Monotherapy |
|---|---|---|---|
| BCVA improvement of >= 1 lettermonth 6 | 93.3 | 96.1 | 63.3 |
| BCVA improvement of >= 1 lettermonth 24 | 89.4 | 93.8 | 77.8 |
| BCVA improvement of >= 5 lettersmonth 6 | 86.1 | 88.2 | 50.0 |
| BCVA improvement of >= 5 lettersmonth 24 | 83.3 | 89.3 | 70.0 |
| BCVA improvement of >= 10 lettersmonth 6 | 66.7 | 68.5 | 41.1 |
| BCVA improvement of >= 10 lettersmonth 24 | 71.1 | 75.8 | 60.0 |
| BCVA improvement of >= 15 lettersmonth 6 | 45.0 | 47.2 | 27.8 |
| BCVA improvement of >= 15 lettersmonth 24 | 52.8 | 59.6 | 43.3 |
| BCVA improvement of >= 30 lettersmonth 6 | 10.0 | 9.6 | 3.3 |
| BCVA improvement of >= 30 lettersmonth 24 | 13.3 | 14.0 | 11.1 |
Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and Month 6 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at Month 6 indicates a positive outcome.
| participants | 1-ranibizumab Monotherapy | 2-ranibizumab With Laser | 3-laser Monotherapy |
|---|---|---|---|
| BCVA improvement of ≥ 1 letter | 168 | 171 | 57 |
| BCVA improvement of ≥ 5 letters N | 155 | 157 | 45 |
| BCVA improvement of ≥ 10 letters | 120 | 122 | 37 |
| BCVA improvement of ≥ 15 letters | 81 | 84 | 25 |
| BCVA improvement of ≥ 30 letters | 18 | 17 | 3 |
| BCVA score ≥ 73 letters | 118 | 97 | 28 |
Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and Month 12 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at Month 24 indicates a positive outcome.
| participants | 1-ranibizumab Monotherapy | 2-ranibizumab With Laser | 3-laser Monotherapy |
|---|---|---|---|
| BCVA improvement of ≥ 1 letter | 161 | 167 | 70 |
| BCVA improvement of ≥ 5 letters | 150 | 159 | 63 |
| BCVA improvement of ≥ 10 letters | 129 | 135 | 54 |
| BCVA improvement of ≥ 15 letters | 95 | 106 | 39 |
| BCVA improvement of ≥ 30 letters | 24 | 25 | 10 |
| BCVA score ≥ 73 letters | 119 | 114 | 41 |
Retinal thickness was measured using Optical Coherence Tomography (OCT). The images were reviewed by a central reading center to ensure a standardized evaluation. Stratification was done based on categories of baseline best corrected visual acuity \& analysis was based on analysis of variance (ANOVA)
| microns | 1-ranibizumab Monotherapy | 2-ranibizumab With Laser | 3-laser Monotherapy |
|---|---|---|---|
| month 12 | -215.9 ± 12.83 | -242.5 ± 14.14 | -203.9 ± 22.22 |
| month 24 | -228.1 ± 12.65 | -261.7 ± 15.20 | -232.7 ± 24.38 |
The survey consists of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. All items are scored so that a high score represents better functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. In this format scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score.
| score on a scale | 1-ranibizumab Monotherapy | 2-ranibizumab With Laser | 3-laser Monotherapy |
|---|---|---|---|
| month 6 composite score | 5.6 ± 9.56 | 4.2 ± 10.41 | 3.7 ± 12.12 |
| month 24 composite score | 8.0 ± 11.78 | 5.0 ± 11.44 | 4.9 ± 14.79 |
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 24 compare to Baseline, the 95% confidence interval and P value (related to the null hypothesis that this mean change is equal to zero) based on a t distribution/t test were calculated and assessed by an ANOVA model.
| BCVA letters | 3- Laser Monotherapy |
|---|---|
| Value at 1st Ranibizumab treatment | 61.7 ± 12.21 |
| Average post 1st treatment through Month 24 | 68.16 ± 11.84 |
| Change from 1st Ranibizumab treatment | 6.49 ± 7.83 |
Collected over [1] Safety set was summarized based on actual treatment received. There were 3 laser monotherapy patients who received ranibizumab and 1 ranibizumab patient who received laser treatment which resulted in percentages > 100% for the ranibizumab + laser arm.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab 0.5mg | — | 30/180 (16.7%) | 112/180 (62.2%) |
| Ranibizumab 0.5mg + Laser | — | 33/183 (18%) | 121/183 (66.1%) |
| Laser Monotherapy With Ranibizumab 0.5 mg From Month 6 | — | 10/63 (15.9%) | 40/63 (63.5%) |
| Laser Monotherapy Without Ranibizumab 0.5 mg From Month 6 | — | 3/25 (12%) | 14/25 (56%) |
| Event | Ranibizumab 0.5mg | Ranibizumab 0.5mg + Laser | Laser Monotherapy With Ranibizumab 0.5 mg From Month 6 | Laser Monotherapy Without Ranibizumab 0.5 mg From Month 6 |
|---|---|---|---|---|
| Gallbladder disorderHepatobiliary disorders | 1/180 | 0/183 | 0/63 | 1/25 |
| PneumoniaInfections and infestations | 0/180 | 1/183 | 0/63 | 1/25 |
| Hip fractureInjury, poisoning and procedural complications | 0/180 | 0/183 | 0/63 | 1/25 |
| Atrial fibrillationCardiac disorders | 3/180 | 1/183 | 0/63 | 0/25 |
| Angina pectorisCardiac disorders | 0/180 | 0/183 | 1/63 | 0/25 |
| ArrhythmiaCardiac disorders | 0/180 | 0/183 | 1/63 | 0/25 |
| Atrioventricular block second degreeCardiac disorders | 1/180 | 0/183 | 1/63 | 0/25 |
| Cardiac arrestCardiac disorders | 0/180 | 0/183 | 1/63 | 0/25 |
| Macular fibrosis (Study eye)Eye disorders | 0/180 | 0/183 | 1/63 | 0/25 |
| Lower respiratory tract infectionInfections and infestations | 1/180 | 0/183 | 1/63 | 0/25 |
| Event | Ranibizumab 0.5mg | Ranibizumab 0.5mg + Laser | Laser Monotherapy With Ranibizumab 0.5 mg From Month 6 | Laser Monotherapy Without Ranibizumab 0.5 mg From Month 6 |
|---|---|---|---|---|
| HypertensionVascular disorders | 19/180 | 22/183 | 7/63 | 2/25 |
| Eye pain (Study eye)Eye disorders | 18/180 | 21/183 | 3/63 | 0/25 |
| HeadacheNervous system disorders | 11/180 | 9/183 | 6/63 | 0/25 |
| Intraocular pressure increased (Study eye)Investigations | 17/180 | 17/183 | 2/63 | 0/25 |
| NasopharyngitisInfections and infestations | 15/180 | 17/183 | 4/63 | 1/25 |
| Conjunctival haemorrhage (Study eye)Eye disorders | 15/180 | 15/183 | 5/63 | 0/25 |
| Ocular hypertension (Study eye)Eye disorders | 5/180 | 4/183 | 0/63 | 2/25 |
| Back painMusculoskeletal and connective tissue disorders | 5/180 | 8/183 | 1/63 | 2/25 |
| InfluenzaInfections and infestations | 13/180 | 13/183 | 2/63 | 1/25 |
| Visual acuity reduced (Study eye)Eye disorders | 5/180 | 6/183 | 4/63 | 1/25 |
| Age, Continuous(years) | 1-ranibizumab Monotherapy | 2-ranibizumab With Laser | 3-laser Monotherapy | Total |
|---|---|---|---|---|
| Mean | 64.7 ± 10.34 | 67.3 ± 10.41 | 67.7 ± 9.67 | 66.3 ± 10.30 |
| Sex: Female, Male(Participants) | 1-ranibizumab Monotherapy | 2-ranibizumab With Laser | 3-laser Monotherapy | Total |
|---|---|---|---|---|
| Female | 90 | 84 | 55 | 229 |
| Male | 93 | 96 | 37 | 226 |
The record gives a start of May 2012, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab